Swiss CDMO Micro-Sphere expands capsule filling capabilities
Contract development and manufacturing organisation Micro-Sphere has invested more than €1.5 million at its plant in Switzerland to expand its offering in encapsulation for inhalation products.
Boosting its existing automatic capsule filling equipment Micro-Sphere has taken delivery of and commissioned a further two MG2 capsule filling machines to increase its low dosage filling capabilities to more than 100,000 capsules per hour.
Michael Grassberger, CEO, Micro-Sphere said: “Micro-Sphere is widely recognized for its expertise in Dry Powder Inhalation encapsulation services of difficult powder formulations. The new machinery will offer high quality products, reduced production times and cost savings for customers who want real commercial benefit.
“This investment is the result of increasing client demand. Added to our existing Harro Höfliger drum dosing equipment, the new MG2 Planeta dosator system means we are one of the few CDMOs in the world to offer these two important commercial size filling techniques under one roof and bridge the gap from development to commercial scale on both techniques for DPIs (dry powder inhalers).
“Both systems are designed for low-dosage filling and have an inline control unit (100% net weight check), FlexaLab (up to 3’000cps/hr.) that is ideal for R&D purposes and small clinical batches, and Planeta (up to 100’000cps/hr) which is scalable for medium-large batch productions. This brings more flexibility for our customers and a best-in-class approach.”
Situated in a new dedicated cleanroom at Micro-Sphere’s EU-GMP, FDA and SwissMedic approved facility near Lugano in Ticino, the MG2 equipment is in an area of controlled temperature and relative humidity of <20%, has a production capability of more than 100,000 cps/hour and increases the CDMO’s manufacturing capacity to up to 600 million capsules per year.
Alongside the MG2 Planeta machine, and for DPIs containing multiple doses, the company has also invested in increasing their containment level (OEB5) and in its DPI testing capabilities with additional Dosage Unit Sampling Apparatus (DUSA) and Next Generation Impactor (NGI).
“This investment sends a strong signal to our customers and partners by increasing our market competitiveness,” added Michael. “As the pharmaceutical industry is under increasing pressure to develop new drugs faster, we are committed to investing in the production capacity, technology and quality systems necessary to continue delivering high-quality, innovative solutions to our customers.”
The new equipment is part of the CDMO’s continued investment into expanding its GMP manufacturing capabilities and comes in response to increased demand for spray drying and inhalables from companies ranging from big pharma to small virtual firms.
Related News
-
News Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Through a collaboration with biotech company Touchlight, Lonza is set to expand their end-to-end offering for mRNA manufacturing with additional DNA raw material sources, including Touchlight’s doggybone DNA. -
News Oxford University presents promising phase II data for malaria vaccine
The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease. -
News NextPharma to acquire Norway manufacturing site from Takeda
Biopharmaceutical company Takeda and CDMO NextPharma have announced an acquisition agreement in which Takeda will divest from their Asker, Norway manufacturing site, set to be acquired by NextPharma. -
News Novavax COVID-19 vaccine receives backing from European Medicines Agency
The European Medicines Agency has backed the Nuvaxovid COVID-19 vaccine for adults as a booster shot to other COVID-19 vaccines. -
News Moderna sues Pfizer/BioNTech over COVID-19 vaccine patent infringement
The pharmaceutical companies behind the leading COVID-19 vaccines are in a legal dispute over intellectual property rights surrounding the mRNA vaccines that were released after emergency use authorization in December 2020. -
News Accepting novel excipients for innovative drug development
With the rapid development and manufacturing of new drugs and therapeutics being pushed through the pipeline, excipient manufacturers are navigating a challenging landscape to meet the demand for new and novel excipients. -
News ChargePoint Technology acquires PuroVaso for greater range of powder and liquid transfer solutions
ChargePoint Technology has acquired PuroVaso, leader in the design, development, and manufacture of single-use containers, handling equipment, and accessories for pharma, biopharma, and life sciences. -
News Lonza adds X-ray powder diffraction to micronisation portfolio in Monteggio (CH)
Lonza expands solid-state characterisation services for polymorph and solid-state properties of APIs with the addition of X-ray powder diffraction to its portfolio.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance